Ann: Appendix 4C & Quarterly Activities Report, page-2

So the YoY numbers can be misleading in terms of accelerating growth. I have compared last 2 quarters sequentially.

Comparing Q4 with Q3 FY2021...
13% growth in revenue
6% ARR increase
14% increase in patient tests

Comparing Q3 with Q2 FY2021
9% growth in revenue
5% ARR increase
14% increase in patient tests

This shows modest acceleration in revenue and ARR bu not in tests as yet.
Current cash runway is 6 quarters.
I think here will be some consolidation of new indications adding to tests and new placement of devices will likely have more impact in next quarter. Some more patience required methinks.